医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2014年
5期
78-79
,共2页
张延霞%郭宗君%王利群%苏玉文
張延霞%郭宗君%王利群%囌玉文
장연하%곽종군%왕리군%소옥문
辛伐他汀%血管性痴呆%hs-CRP
辛伐他汀%血管性癡呆%hs-CRP
신벌타정%혈관성치태%hs-CRP
Simvastatin%vascular dementia%hs-CRP
目的:观察辛伐他汀口服对VD患者hs-CRP的影响,并观察治疗前后MMSE评分的变化。方法选择2012.5~2013.11我科收治的VD患者60例,分为辛伐他汀治疗组(即治疗组)30例和对照组30例,其中治疗组男22例,女8例;对照组男21例,女9例,两组均给予阿司匹林、尼莫地平及相同的活血化瘀药物等常规治疗及对症处理,治疗组在此基础上给予口服辛伐他汀片,治疗前及治疗后24W行hs-CRP检测及MMSE评分。结果24W后,治疗组较对照组患者的hs-CRP水平显著降低(P<0.05), MMSE 评分显著升高(P<0.05)。结论辛伐他汀联合阿司匹林、尼莫地平等常规药物治疗血管性痴呆疗效显著,无明显不良反应,临床中值得推广。
目的:觀察辛伐他汀口服對VD患者hs-CRP的影響,併觀察治療前後MMSE評分的變化。方法選擇2012.5~2013.11我科收治的VD患者60例,分為辛伐他汀治療組(即治療組)30例和對照組30例,其中治療組男22例,女8例;對照組男21例,女9例,兩組均給予阿司匹林、尼莫地平及相同的活血化瘀藥物等常規治療及對癥處理,治療組在此基礎上給予口服辛伐他汀片,治療前及治療後24W行hs-CRP檢測及MMSE評分。結果24W後,治療組較對照組患者的hs-CRP水平顯著降低(P<0.05), MMSE 評分顯著升高(P<0.05)。結論辛伐他汀聯閤阿司匹林、尼莫地平等常規藥物治療血管性癡呆療效顯著,無明顯不良反應,臨床中值得推廣。
목적:관찰신벌타정구복대VD환자hs-CRP적영향,병관찰치료전후MMSE평분적변화。방법선택2012.5~2013.11아과수치적VD환자60례,분위신벌타정치료조(즉치료조)30례화대조조30례,기중치료조남22례,녀8례;대조조남21례,녀9례,량조균급여아사필림、니막지평급상동적활혈화어약물등상규치료급대증처리,치료조재차기출상급여구복신벌타정편,치료전급치료후24W행hs-CRP검측급MMSE평분。결과24W후,치료조교대조조환자적hs-CRP수평현저강저(P<0.05), MMSE 평분현저승고(P<0.05)。결론신벌타정연합아사필림、니막지평등상규약물치료혈관성치태료효현저,무명현불량반응,림상중치득추엄。
Objective To observe the effects of aspirin, simvastatin on VD of patients with hs-CRP, and observe the change of MMSE score before and after treatment. Methods Choose 2012.5 to 2013.11 in our hospital from 60 VD patients, divided into simvastatin group (treatment group) 30 cases and control group 30 cases, the treatment group male 22 cases, female 8 cases; control group, male 21 cases, female 9 cases, the two groups were given aspirin、Nimodipine and the same blood circulation drugs routine treatment and symptomatic treatment, the treatment group based on the given oral Simvastatin Tablets, before treatment and 24W after treatment were detected with hs-CRP and MMSE score. Results 24W later, the treatment group was significantly lower than the control group of patients with hs-CRP (P<0.05), MMSE score was significantly increased (P<0.05).Conclusion Effect of simvastatin and aspirin、Nimodipine on vascular dementia and other conventional drug treatment significantly, no significant adverse reactions, worthy of promotion in clinical therapy.